Similar Articles |
|
The Motley Fool October 28, 2004 Brian Gorman |
Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K. |
The Motley Fool July 28, 2004 Brian Gorman |
Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge. |
The Motley Fool October 26, 2005 Stephen D. Simpson |
Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it. |
The Motley Fool December 10, 2004 Brian Gorman |
Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction. |
The Motley Fool June 13, 2006 Ryan Fuhrmann |
Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment. |
The Motley Fool January 30, 2006 Brian Gorman |
Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note. |
The Motley Fool June 28, 2005 Brian Gorman |
Cardinal Changes Course The health care company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news. |
The Motley Fool November 7, 2007 Billy Fisher |
Cardinal Has Its Wings Clipped Despite a healthy year-over-year pop of 15% in EPS from operations, much of the focus in the first-quarter was shifted to a weak performance by Cardinal's pharmaceutical services segment. |
The Motley Fool May 6, 2005 W.D. Crotty |
McKesson's New Pep Pill The drug wholesaler reports strong fourth-quarter results as it moves to a fee-for-service model. |
The Motley Fool January 26, 2007 Billy Fisher |
A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note. |
The Motley Fool August 3, 2006 Ryan Fuhrmann |
Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC. |
The Motley Fool May 2, 2005 Brian Gorman |
Cardinal Health Perks Up The drug distribution company is working through its problems, which should make for a brighter fiscal 2006. Investors, take note. |
The Motley Fool January 18, 2005 Brian Gorman |
Cardinal Doesn't Get Ruffled The drug distributor's potential loss of Japanese pharmaceutical Eisai will hurt in the short term, but fortunately for investors Cardinal Health continues to plan wisely. |
The Motley Fool September 30, 2008 Brian Orelli |
Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business? |
The Motley Fool May 20, 2004 Tom Taulli |
Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth. |
The Motley Fool January 2, 2004 Alyce Lomax |
A Bitter Pill for Amerisource Veterans ditch Amerisource for rival; investors punish the entire pharmaceutical distribution industry. |
The Motley Fool July 1, 2004 W.D. Crotty |
Drug Wholesalers Taking a Beating A sharp drop at drug wholesaler Cardinal Health provides a unique buying opportunity. |
The Motley Fool October 8, 2007 Billy Fisher |
McKesson Expands Its Empire A new acquisition strengthens the company's presence in the cancer drug market. Investors, take note. |
The Motley Fool January 21, 2005 Rich Duprey |
Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all. |
The Motley Fool October 18, 2005 Stephen D. Simpson |
More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note. |
BusinessWeek November 24, 2003 Roger O. Crockett |
Cardinal Health, Heal Thyself CEO Walter aims to revive growth, selling high-tech gear and expanding overseas. |
The Motley Fool November 8, 2011 Brandon Glenn |
Cardinal Health Looks to Build China Business, but Has Long Way to Go For pharmaceuticals distributor Cardinal Health, China represents a world of opportunity. |
The Motley Fool August 24, 2011 Brandon Glenn |
Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge? |
The Motley Fool April 26, 2004 Alyce Lomax |
Amerisource Hangs On While pharmaceutical distribution is an industry with obvious opportunities for financial reward, the potential for a price war remains a risk. |
Financial Planning September 1, 2007 Glenn G. Kautt |
Helping the Handoff Survey results show that business owners are in need of help when it comes to transition planning. There are four phases in the transition of a business where advisors can help their clients. |
The Motley Fool June 27, 2011 Brandon Glenn |
Cardinal Health Products Won't Be in Cleveland Medical Mart (or Any Other) Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health has had an apparent change of opinion. |
The Motley Fool October 12, 2004 W.D. Crotty |
A Bargain in Drug Distribution? D&K Healthcare Resources' stock surprises investors, but the drop brings a favorable valuation. |
The Motley Fool April 19, 2006 Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
The Motley Fool April 7, 2011 Brandon Glenn |
"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors. |
The Motley Fool March 23, 2011 Jordan DiPietro |
Should You Buy and Hold Cardinal Health? Does this company have the traits of a good retirement stock? |
Pharmaceutical Executive October 1, 2011 |
30 Years of Pharma: Perspective in Numbers Top 10 pharmaceutical products worldwide. |
The Motley Fool April 15, 2005 Selena Maranjian |
You're Too Late for This Fund When one good fund closes, others are still open. |
The Motley Fool July 28, 2005 Tom Taulli |
Is Sun Getting Eclipsed? Maybe the best strategy for Sun is just to give money back to its shareholders. |
The Motley Fool May 2, 2008 Steven Renaldi |
Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it. |
Pharmaceutical Executive November 1, 2008 Tousi & Lee |
Making Sense of Sales The direct sales force is one of the largest costs for most pharma companies, but don't throw out sales force effectiveness with the sales force when cutting costs. Read on for some sure-fire strategies. |
Chemistry World March 3, 2015 Phillip Broadwith |
J&J to sell cardiac devices to wholesaler Cardinal Johnson & Johnson has agreed to sell its cardiovascular surgical devices subsidiary, Cordis, to wholesale supplier Cardinal Health. |
The Motley Fool May 18, 2004 Selena Maranjian |
A Daring but Doomed Proposal What if shareholders decided how companies spent their money? |
The Motley Fool January 26, 2005 Stephen D. Simpson |
Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation. |
The Motley Fool August 17, 2007 Brian Lawler |
The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition. |
Pharmaceutical Executive February 1, 2011 Frederic Brunner |
Growing Stronger After the Storm To manage through a resource-constrained environment, it is essential to get the most out of procurement planning |
The Motley Fool June 14, 2007 Nathan Parmelee |
Target Releases Arrows Made of Money The retailer has done well by shareholders, and might do even better. |
Pharmaceutical Executive October 1, 2011 |
30 Years of Pharma: Perspective in Numbers, Part 2 Top 10 pharmaceutical companies by market share. |
The Motley Fool May 6, 2008 Steven Renaldi |
McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry. |
The Motley Fool May 6, 2008 Alyce Lomax |
When Shareholders Speak ... AFLAC Listens The insurance company blazes a trail in letting shareholders have a say on management's pay. |
BusinessWeek August 30, 2004 Gene G. Marcial |
PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell. |
The Motley Fool December 8, 2004 Alyce Lomax |
Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days. |